Comparison of Sequential to Initial Combination Therapy in PAH

NARecruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2028

Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
DRUG

Tadalafil

Target dose 40 mg OD

DRUG

Ambrisentan

Target dose 10 mg OD

DRUG

Ambrisentan mimic

Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.

DRUG

Tadalafil mimic

Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.

Trial Locations (1)

310058

RECRUITING

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Huzhou Central Hospital

OTHER

collaborator

Ningbo Medical Center Lihuili Hospital

OTHER_GOV

collaborator

First Affiliated Hospital of Ningbo University

NETWORK

collaborator

Ningbo No.2 Hospital

OTHER

collaborator

Affiliated Hospital of Jiaxing University

OTHER

collaborator

The Second Affiliated Hospital of Jiaxing University

OTHER

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Shanghai Pulmonary Hospital affiliated to Tongji University

UNKNOWN

collaborator

Taizhou Hospital

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER